Comparative efficacy of enalapril and valsartan in heart failure with mid-range ejection fraction

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access


Aim. To compare the effectiveness of the angiotensin-converting enzyme inhibitor enalapril and the angiotensin II receptor antagonist valsartan in patients with heart failure with mid-range ejection fraction (HFmrEF) from the standpoint of the effect on the clinical picture, echocardiographic parameters and the level of the N-terminal fragment of the prohormone brain-type sodium (NT-proBNP).

Methods. 110 patients with heart failure with mid-range ejection fraction were included in the study based on the City Clinical Hospital named after N.I. Pirogov of Orenburg between 2018 and 2020. All patients were divided into two randomized groups. Patients of the first group (n=55) were prescribed enalapril, the second group (n=55) — valsartan. Each patient was followed up for 1 year. The six-minute walk test, NT-pro-brain natriuretic peptide level, echocardiography parameters were assessed in dynamics. Statistical analysis was performed by using Statistica 10.0 software, Shapiro–Wilk, Mann–Whitney, Wilcoxon tests.

Results. During the year of observation in both groups, there was a significant decrease in the functional class of chronic heart failure (p <0.005) without a statistical difference between the groups (p=0.251). The distance during the six-minute walk test increased from 350 (310–400) m to 490 (420–530) m (p <0.001) in the first group, from 360 (330–400) m to 510 (450–520) m (p <0.001) in the second group, also without significant differences (p=0.361). The NT-pro-brain natriuretic peptide level decreased from 491 (410–610) pg/ml to 286 (187–350) pg/ml (p <0.001) in the first group, and from 446 (376–534) pg/ml to 210 (143–343) pg/ml (p <0.001) in the second, with a more significant change in the second group (p=0.020). The dynamics of echocardiography parameters were comparable in the groups (p >0.05), while ejection fraction normalized in 89.1% of patients received enalapril and 92.7% of patients received valsartan.

Conclusion. The efficacy of enalapril and valsartan in heart failure with mid-range ejection fraction is comparable in its effect on the clinical picture and echocardiography parameters with a more pronounced decrease in NT-pro-brain natriuretic peptide when taking valsartan during a year of follow up.

Full Text

Restricted Access

About the authors

T. A. Glebova

City Clinical Hospital named after N.I. Pirogov

Author for correspondence.
ORCID iD: 0000-0001-6081-8144
SPIN-code: 5253-1403
Russian Federation, Orenburg, Russia

P. Yu Galin

Orenburg State Medical University

ORCID iD: 0000-0003-3114-478X
SPIN-code: 1279-5300
Scopus Author ID: 36820987300
ResearcherId: Р-3892-2015
Russian Federation, Orenburg, Russia


  1. Shlyakhto E.V., Baranova E.I. Central directions for reducing cardiovascular mortality: what can be changed today? Russian Journal of Cardiology. 2020; 25 (7): 10–18. (In Russ.) doi: 10.15829/1560-4071-2020-3983.
  2. Rastogi A., Novak E., Platts A.E., Mann D.L. Epidemiology, pathophysiology and clinical outcomes for heart failure patients with a mid-range ejection fraction. Eur. J. Heart Fail. 2017; 19: 1597–605. doi: 10.1002/ejhf.879.
  3. Fomin I.V. Chronic heart failure in Russian Federation: what do we know and what to do. Russian Journal of Cardiology. 2016; (8): 7–13. (In Russ.) doi: 10.15829/1560-4071-2016-8-7-13.
  4. Ponikowski P., Voors A.A., Anker S.D., Bueno H., Cleland J.G.F., Coats A.J.S., Falk V., González-Juana­tey J.R., Harjola V.P., Jankowska E.A., Jessup M., Linde C., Nihoyannopoulos P., Parissis J.T., Pieske B., Riley J.P., Rosano G.M.C., Ruilope L.M., Ruschitzka F., Rutten F.H., van der Meer P. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) ­Developed with the special contribution of the Heart Fai­lure Association (HFA) of the ESC. Eur. Heart J. 2016; 37 (27): 2129–2200. doi: 10.1093/eurheartj/ehw128.
  5. Bozkurt B., Coats A.J.S., Tsutsui H., Abdelha­mid C.M., Adamopoulos S., Albert N., Anker S.D., Ather­ton J., Böhm M., Butler J., Drazner M.H., Michael Felker G., Filippatos G., Fiuzat M., Fonarow G.C., Gomez-Mesa J.E., Heidenreich P., Imamura T., Jankowska E.A., Januzzi J., Khazanie P., Kinugawa K., Lam C.S.P., Matsue Y., Metra M., Ohtani T., Francesco Piepoli M., Poni­kowski P., Rosano G.M.C., Sakata Y., Seferović P., Starling R.C., Teerlink J.R., Vardeny O., Yamamoto K., Yancy C., Zhang J., Zieroth S. Universal definition and classification of heart failure. J. Cardiol. Fail. 2021; 27 (4): 387–413. doi: 10.1016/j.cardfail.2021.01.022.
  6. Ageev F.T., Ovchinnikov A.G. Heart failure with mid-range ejection fraction: are there clinical reasons in introduction of this new group as a distinct entity? Kardiologia. 2018; 58 (12S): 4–10. (In Russ.) doi: 10.18087/cardio.2609.
  7. Lund L.H., Vedin O., Savarese G. Is ejection fraction in heart failure a limitation or an opportunity? Viewpoint. Eur. J. Heart Fail. 2018; 20 (3): 431–432. doi: 10.1002/ejhf.1106.
  8. Tsuji K., Sakata Y., Nochioca K., Miura M., Yamauchi T., Onose T., Abe R., Oikawa T., Kasahara S., Sato M., Shiroto T., Takahashi J., Miyata S., Shimokawa H. Characterization of heart failure patients with mid-range left ventricular ejection fraction — a report from the CHART-2 Study. Eur. J. Heart Fail. 2017; 19: 1258–1269. doi: 10.1002/ejhf.807.
  9. Feng J.L., Qin X. Association between evidence-based medication at discharge and outcomes in patients with heart failure: A systematic review and meta-analysis. Heart Fail. Rev. 2021; 26: 81–89. doi: 10.1007/s10741-019-09900-3.
  10. Mareev V.Yu., Fomin I.V., Ageev F.T., Begrambekova Yu.L., Vasyuk Yu.A., Garganeeva A.A., Gendlin G.E., Glezer M.G., Gautier S.V., Dovzhenko T.V., Kobalava Z.D., Koziolova N.A., Koroteev A.V., Mareev Yu.V., Ovchinnikov A.G., Perepech N.B., Tarlovskaya E.I., Chesnikova A.I., Shevchenko A.O., Arutyunov G.P., Belenkov Yu.N., Galyavich A.S., Gi­lyarevsky S.R., Drapkina O.M., Duplyakov D.V., Lopatin Yu.M., Sitnikova M.Yu., Skibitsky V.V., Shlyakhto E.V. Russian Heart Failure Society, Russian Society of Cardio­logy, Russian Scientific Medical Society of Internal Medicine. Guidelines for Heart failure: chronic (CHF) and acute decompensated (ADHF). Diagnosis, prevention and treatment. Kardiologia. 2018; 58 (S6): 8–158. (In Russ.) doi: 10.18087/cardio.2475.
  11. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N. Engl. J. Med. 1991; 325 (5): 293–302. doi: 10.1056/NEJM199108013250501.
  12. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N. Engl. J. Med. 1987; 316: 1429–1435. doi: 10.1056/NEJM198706043162301.
  13. Cohn J.N., Tognoni G.A. Randomized trial of the angiotensin-receptor blocker valsartan in chronic heart fai­lure. N. Engl. J. Med. 2001; 345: 1667–1675. doi: 10.1056/NEJMoa010713.
  14. Aliyeva A.M., Reznik E.V., Hasanova E.T., Zhbanov I.V., Nikitin I.G. Clinical value of blood biomar­kers in patients with chronic heart failure. The Russian Archives of Internal Medicine. 2018; 8 (5): 333–345. (In Russ.) doi: 10.20514/2226-6704-2018-8-5-333-345.
  15. Farzutdinov A.F., Zatevakhina M.V. Pathophisiology of postinfarction aneurysm of left ventricle. Anesteziologiya i reanimatologiya. 2016; 61 (4): 244–248. (In Russ.) doi: 10.18821/0201-7563-2016-4-244-248.

Supplementary files

There are no supplementary files to display.

© 2021 Eco-Vector

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies